[go: up one dir, main page]

AU2001235668A1 - Xanthine derivatives, intermediates and use for treating osteoporosis - Google Patents

Xanthine derivatives, intermediates and use for treating osteoporosis

Info

Publication number
AU2001235668A1
AU2001235668A1 AU2001235668A AU3566801A AU2001235668A1 AU 2001235668 A1 AU2001235668 A1 AU 2001235668A1 AU 2001235668 A AU2001235668 A AU 2001235668A AU 3566801 A AU3566801 A AU 3566801A AU 2001235668 A1 AU2001235668 A1 AU 2001235668A1
Authority
AU
Australia
Prior art keywords
intermediates
xanthine derivatives
treating osteoporosis
derivatives
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001235668A
Inventor
Gunter Johannes Billen
Yamina Bouali
Francois Nique
Yusuke Satoh
Jean-Paul Vevert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU2001235668A1 publication Critical patent/AU2001235668A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns xanthine derivatives of formula (I) and their salts wherein: R1 represents a monocyclic or polycyclic system containing 0, 1, 2, 3 or 4 substituted or unsubstituted heteroatoms; R2 = H, R4, -(CH2)n-R4 or (CH2)m-O-R4, with R4 = R1 or substituted or unsubstituted alkyl; R3 = H; n and m = 1, 2 or 3. The invention also concerns the method for preparing said derivatives and intermediates of said method, their use as medicine and pharmaceutical compositions containing them.
AU2001235668A 2000-02-15 2001-02-14 Xanthine derivatives, intermediates and use for treating osteoporosis Abandoned AU2001235668A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0001845 2000-02-15
FR0001845A FR2804958B1 (en) 2000-02-15 2000-02-15 XANTHINE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENT AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
PCT/FR2001/000420 WO2001060824A1 (en) 2000-02-15 2001-02-14 Xanthine derivatives, intermediates and use for treating osteoporosis

Publications (1)

Publication Number Publication Date
AU2001235668A1 true AU2001235668A1 (en) 2001-08-27

Family

ID=8847004

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001235668A Abandoned AU2001235668A1 (en) 2000-02-15 2001-02-14 Xanthine derivatives, intermediates and use for treating osteoporosis

Country Status (9)

Country Link
EP (1) EP1257552B1 (en)
AT (1) ATE273979T1 (en)
AU (1) AU2001235668A1 (en)
DE (1) DE60104986T2 (en)
DK (1) DK1257552T3 (en)
ES (1) ES2227134T3 (en)
FR (1) FR2804958B1 (en)
PT (1) PT1257552E (en)
WO (1) WO2001060824A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1521584A1 (en) 2002-06-17 2005-04-13 Glaxo Group Limited Purine derivatives as liver x receptor agonists
JP5869222B2 (en) 2008-01-04 2016-02-24 インテリカイン， エルエルシー Specific chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX347708B (en) 2011-01-10 2017-05-09 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones.
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2702908C2 (en) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Treating malignant tumours using modulators of pi3-kinase isoforms
WO2015003881A1 (en) * 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
MX391135B (en) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc COMBINATION THERAPIES.
CN109503583A (en) * 2018-12-14 2019-03-22 南京纽邦生物科技有限公司 The preparation method of 1,7- dimethyl xanthine and its intermediate, intermediate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2094270C (en) * 1990-10-18 1997-01-21 Fumio Suzuki Xanthine derivatives
JPH11505241A (en) * 1995-05-19 1999-05-18 カイロサイエンス・リミテッド Xanthines and their therapeutic use
JPH09169665A (en) * 1995-12-21 1997-06-30 Kenichi Miyamoto Agent for treatment osteoporosis
ATE226583T1 (en) * 1996-06-07 2002-11-15 Hoechst Ag USE OF THEOPHYLLINE DERIVATIVES FOR THE TREATMENT AND PROPYLAXIS OF SHOCK CONDITIONS, NEW XANTHINE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
JPH1192379A (en) * 1997-07-24 1999-04-06 Kunio Takaoka Agent for preventing or treating bone disease

Also Published As

Publication number Publication date
EP1257552A1 (en) 2002-11-20
DK1257552T3 (en) 2004-12-20
DE60104986D1 (en) 2004-09-23
WO2001060824A1 (en) 2001-08-23
DE60104986T2 (en) 2005-08-25
PT1257552E (en) 2005-01-31
ATE273979T1 (en) 2004-09-15
ES2227134T3 (en) 2005-04-01
FR2804958A1 (en) 2001-08-17
EP1257552B1 (en) 2004-08-18
FR2804958B1 (en) 2005-07-08

Similar Documents

Publication Publication Date Title
BG105925A (en) Novel tricyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
IL127296A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO1999008501A3 (en) New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
YU70901A (en) 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
WO1999064409A3 (en) Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use
MX9302214A (en) DERIVATIVES OF TAXOL AND PROCESS FOR ITS PREPARATION
ATE203515T1 (en) META-SUBSTITUTED PHENYLSULPHONAMIDE DERIVATIVES
MY121760A (en) Benzothiazin and benzoxazin derivatives;their preparation and uses
AR024390A1 (en) NEW COMPOUNDS
DK0889875T3 (en) Cycloproylalkanoic acid derivatives
DE3373306D1 (en) Succinimide derivatives and their production
NZ236293A (en) 1-(alkyl or alkoxyalkyl)-4-phenyl piperidine-4-carboxylic acid amide derivatives; preparatory processes and pharmaceutical compositions
CA2238845A1 (en) Novel 2,3,5-trimethyl-4-hydroxy anilide derivatives, preparation thereof and therapeutical use thereof
BG106932A (en) Novel compounds having hypolipedemic and hypocholesteremic activities, processes for their preparation and pharmaceutical compositions containing them
HUT59394A (en) Process for producing piperazine derivatives and pharmaceutical compositions comprising same
AU2001235668A1 (en) Xanthine derivatives, intermediates and use for treating osteoporosis
EP1077218A3 (en) Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
EG20726A (en) Process for preparing of galanthamine derivatives as acetylchol inc-sterase inhibitors
ATE231160T1 (en) ERYTHROMYCIN DERIVATIVES, THEIR PROCESS FOR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS
HU9802143D0 (en) New heterocyclic compounds of 5 members in the ring, process for producing them and pharmaceutical compositions containing them
EP0712398A1 (en) BENZOPYRANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SI1049686T1 (en) Intermediates and methods useful in the semisynthesis of paclitaxel and analogs
BR9610175A (en) Compound preparation process of the pharmaceutical composition and use of the compound
EP0245902A3 (en) Benzothiazinone derivatives
AU2002218422A1 (en) New desloratadine salts, process for their synthesis and pharmaceutical compositions thereof